SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members
of its senior management team will participate at the upcoming
investor conferences:
- Evercore ISI HealthCONx Conference – Presenting on Tuesday, December 3, at 11:00 AM ET in Boston
- Citi Global Healthcare Conference – Hosting investor meetings
on Wednesday, December 11, in
New York City
A live audio webcast of the Evercore presentation will be
posted under the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena
Pharmaceuticals is driven to deliver novel, transformational
medicines with optimized pharmacology to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Arena is
evaluating etrasimod (APD334) in a broad range of
immune-mediated inflammatory diseases, including in later-stage
programs in inflammatory bowel disease (IBD), a Phase 2 program in
atopic dermatitis (AD), and in programs for other indications.
Arena is also evaluating olorinab (APD371) in a Phase 2
program for gastrointestinal pain. Arena continues to assess other
earlier research and development stage drug candidates,
including APD418 for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase
3 program for pulmonary arterial hypertension), Everest
Medicines Limited (etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International
GmbH (undisclosed target – preclinical), Outpost
Medicine, LLC (OP-352 – Phase 1), and Eisai Co.,
Ltd. and Eisai Inc. (BELVIQ® –
marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming conferences and Arena's drive,
assets, programs, licenses, and partnerships. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include
those disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-300965006.html
SOURCE Arena Pharmaceuticals, Inc.